Table 3.

CMR-FT model. Uni- and multivariable Cox analysis to predict MACEs (primary end-point)^*.

	Univariable analysis HR (95% CI)	p	Multivariable analysis HR (95% CI)	p
Clinical data
NYHA III-IV	3.97 (2.15–7.33)	<0.0001	2.98 (1.60–5.55)	0.001
Sinus rhythm	0.25 (0.12–0.53)	<0.0001	0.35 (0.17–0.75)	0.007
Standard CMR-data
LVEDVi, ml/m2	1.01 (1–1.02)	<0.0001
RVEDVi, ml/m2	1.02 (1.01–1.03)	<0.0001
LVEF, %	1.08 (1.04–1.11)	<0.0001
RVEF, %	1.05 (1.03–1.08)	<0.0001
LGE presence	3.14 (1.54–6.4)	0.002	2.51 (1.22–5.13)	0.012
CMR-FT strain values
LV peak GLS, %	1.08 (1.02–1.15)	0.008
RV peak GLS, %	1.06 (1.02–1.1)	0.001	1.06 (1.02–1.1)	0.008

CI, confidence interval; CMR, cardiac magnetic resonance; FT, feature tracking; GCS, global circumferential strain; GLS, global longitudinal strain; GRS, global radial strain; HR, hazard ratio; LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, left ventricle end diastolic volume indexed; LVEF, left ventricle ejection fraction; RV, right ventricle; RVEF, right ventricle ejection fraction.

Only significant variables were reported in univariable analysis.

^*MACEs were considered as the study primary outcome measure and were defined as a composite of: (a) cardiovascular death, (b) cardiac transplant or destination therapy ventricular assist device for end-stage heart failure (HF), (c) hospitalization for life-threatening ventricular arrhythmias or implanted cardioverter defibrillator appropriate intervention on sustained ventricular tachycardia >185 beats per minute or ventricular fibrillation.